Showing results (321-330 of 355) with videos related to

Sort By:
Pageof 36
Clinical Rheumatology|March 3, 2021
The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trialAlexis Ogdie, Jessica A Walsh, Soumya D Chakravarty, et al.
Clinical Rheumatology|October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatmentPhilip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
Rheumatology and Therapy|August 19, 2023
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
Rheumatology (Oxford, England)|April 12, 2021
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysisPhilip J Mease, Iain B McInnes, Lai-Shan Tam, et al.
The Prostate|March 27, 2015
Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern IndiaBushra Ateeq, Lakshmi P Kunju, Shannon L Carskadon, et al.
ACR Open Rheumatology|February 28, 2024
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
ACR Open Rheumatology|October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled StudyPhilip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Dermatology and Therapy|November 25, 2021
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis RegistryJessica A Walsh, Kristina Callis Duffin, Abby S Van Voorhees, et al.
Annals of the Rheumatic Diseases|September 17, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX studyPhilip J Mease, Christopher T Ritchlin, Laura C Coates, et al.
Tropical Medicine and Infectious Disease|November 6, 2019
Active Case Finding for Tuberculosis through TOUCH Agents in Selected High TB Burden Wards of Kolkata, India: A Mixed Methods Study on Outcomes and Implementation ChallengesAbhijit Dey, Pruthu Thekkur, Ayan Ghosh, et al.
Pageof 36